Prevalence and Induction of Circulating Antibodies against Recombinant Staphylokinase

 

PDF Download Buy Article Permissions and Reprints

Summary

Streptokinase (SK) is a routinely used thrombolytic agent but it is immunogenic and allergenic; staphylokinase (STA) is a potential alternative agent which is under early clinical evaluation. The comparative prevalence of antibodies against recombinant STA (STAR) and against SK was studied in healthy subjects and their induction with intravenous administration in small groups of patients.

Enzyme-linked immunosorbent assays, using microtiter plates coated with STAR or SK and calibration with affinospecific human antibodies, revealed 2.1 to 65 μg/ml (median 11 μg/ml) anti-STAR antibodies and 0.9 to 370 μg/ml (median 18 μg/ml) anti-SK antibodies (p <0.001 vs anti-STAR antibodies) in plasma from 100 blood donors, with corresponding values of 0.6 to 100 μg/ml (median 7.1 μg/ml) and 0.4 to 120 μg/ml (median 7.3 μg/ml), respectively, in 104 patients with angina pectoris. Three out of 17 patients with Staphylococcus aureus bacteremia had significantly increased anti-STAR antibody levels (150, 75 and 75 μg/ml), and STAR neutralizing activities (2.2, 3.6 and 4.1 μg STAR neutralized per ml plasma, respectively). In 6 patients with acute myocardial infarction, given 10 mg STAR intravenously over 30 min, median anti-STAR antibody levels were 3.5 μg/ml at baseline, 2.9 μg/ml at 6 to 8 days and 1.2 μg/ml at 2 to 9 weeks, with median corresponding titers of STAR neutralizing activity at 2 to 9 weeks of 42 μg/ml plasma. Conversely, in 5 patients treated with 1,500,000 units SK over 60 min, median anti-SK antibodies increased from 2.9 μg/ml at baseline to 360 μg/ml at 5 to 10 days, with corresponding median SK neutralizing activities of 13 μg/ml. Antibodies against STAR did not cross-react with SK and vice versa.

Plasma from human subjects contains low levels of circulating antibodies against recombinant staphylokinase, and intravenous administration of this compound boosts antibody titers. These antibodies do however not cross-react with streptokinase, whereby the use of these two immunogenic thrombolytic agents would not be mutually exclusive.

• References

• 1 Verstraete M, Vermylen J, Amery A, Vermylen C. Thrombolytic therapy with streptokinase using a standard dosage scheme. Br Med J 1966; 1: 454-6
  CrossrefPubMedGoogle Scholar
• 2 James DC O. Anti-streptokinase levels in various hospital patient groups. Postgrad Med J 1973; 49 Suppl I 26-9
  PubMedGoogle Scholar
• 3 Moran DM, Standring R, Lavender EA, Harris GS. Assessment of Anti-Streptokinase Antibody levels in human sera using a microradioimmunoassay procedure. Thromb Haemostas 1984; 52: 281-7
  PubMedGoogle Scholar
• 4 De Bono D. Problems in thrombolysis. In: Thrombolysis in Cardiovascular Disease. Julian D. et al. (eds) Marcel Dekker Inc; New York: 1989: 272-92
  Google Scholar
• 5 Mc Grath K, Patterson R. Immunology of streptokinase in human subjects. Clin Exp Immunol 1985; 62: 421-6
  PubMedGoogle Scholar
• 6 Fitzgerald DJ, Catella F, Louis R, Fitz Gerald FA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77: 142-50
  CrossrefPubMedGoogle Scholar
• 7 Vaughan DE, Kirshenbaum JM, Loscalzo J. Streptokinase-induced, antibody-mediated platelet aggregation: A potential cause of clot propagation in vivo. J Am Coll Cardiol 1988; 11: 1343-8
  CrossrefPubMedGoogle Scholar
• 8 Vaughan DE, Van Houtte E, Declerck PJ, Collen D. Streptokinase-induced platelet aggregation: prevalence and mechanism. Circulation 1991; 84: 84-91
  CrossrefPubMedGoogle Scholar
• 9 Lynch M, Littler WA, Pentecost BL, Stockley RA. Immunoglobulin response to intravenous streptokinase in acute myocardial infarction. Br Heart J 1991; 66: 139-42
  CrossrefPubMedGoogle Scholar
• 10 Jalihal S, Morris GK. Antistreptokinase titers after intravenous streptokinase. Lancet 1990; 335: 184-5
  CrossrefPubMedGoogle Scholar
• 11 White H. Thrombolytic treatment for recurrent myocardial infarction. Brit Med J 1991; 302: 429-30
  CrossrefPubMedGoogle Scholar
• 12 Lack CH. Staphylokinase: an activator of plasma protease. Nature 1948; 161: 559-60
  PubMedGoogle Scholar
• 13 Collen D, De Cock F, Vanlinthout I, Declerck PJ, Lijnen HR, Stassen JM. Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis 1992; 6: 232-42
  PubMedGoogle Scholar
• 14 Collen D, De Cock F, Stassen JM. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation 1993; 87: 996-1006
  CrossrefPubMedGoogle Scholar
• 15 Sweet B, Mc Nicol GP, Douglas AS. In vitro studies of staphylokinase. Clin Sci 1965; 29: 375-82
  PubMedGoogle Scholar
• 16 Collen D, Silence K, Demarsin E, De Mol M, Lijnen HR. Isolation and characterization of natural and recombinant staphylokinase. Fibrinolysis 1992; 6: 203-13
  PubMedGoogle Scholar
• 17 Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993; 87: 1850-3
  CrossrefPubMedGoogle Scholar
• 18 Amery A, Maes H, Vermylen J, Verstraete M. The streptokinase reactivity test. I. Standardization. Thromb Diath Haemorrh 1963; 9: 175-88
  PubMedGoogle Scholar
• 19 Bachmann F. Development of antibodies against perorally and rectally administered streptokinase in man. J Lab Clin Med 1968; 72: 228-38
  PubMedGoogle Scholar